Showing 2391-2400 of 4116 results for "".
- Study Links Radioactive Iodine Therapy to Increased Melanoma Riskhttps://practicaldermatology.com/news/study-links-radioactive-iodine-therapy-increased-melnoma-risk/2468325/A new study found elevated risk of melanoma and other nonkeratinocyte skin cancers in patients with primary thyroid cancer who received radioactive iodine therapy, particularly in the head and neck region. In the JAMA Network Open article “Development of Melanoma and Other Nonkeratinocyte
- Tralokinumab Data for H&N AD Presented at EADVhttps://practicaldermatology.com/news/tralokinumab-data-hn-ad-presented-eadv/2468323/Nine-month interim data from the TRACE study, showing that tralokinumab/tralokinumab-ldrm reduced the severity of moderate-to-severe atopic dermatitis (AD) in the head and neck region of the body (H&N), were shared through one of LEO Pharma’s five late-breaking oral presentations at the 33rd
- Survey: Majority of Physicians Report Feelings of Burnouthttps://practicaldermatology.com/news/survey-majority-physicians-report-feelings-burnout/2468314/A majority of physicians reported feelings of burnout in 2024, according to a new survey. Researchers for the 2024 Survey of America's Current and Future Physicians, which focuses on the state of physician, resident, and medical student wellbeing, included 1,723 responses and co
- SEEN Hair Care Closes $9 Million in Series A Fundinghttps://practicaldermatology.com/news/seen-hair-care-closes-9-million-series-funding/2468305/SEEN, the award-winning haircare brand developed by dermatologist Iris Rubin, MD, has closed a $9 million Series A funding. The company said in a press release that this investment will “accelerate SEEN's growth as the premier science-backed, clinically-proven beauty brand, which sits at the inte
- New Deuruxolitinib Data to Be Presented at EADVhttps://practicaldermatology.com/news/new-deuruxolitinib-data-be-presented-eadv/2468304/Sun Pharma will present new clinical data on the JAK1/JAK2 inhibitor deuruxolitinib at the 2024 European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, Netherlands from September 25-28, the company announced. Deuruxolitinib, which Sun Pharma provides under the name LE
- Kenvue to Present New Data Sets at EADV Congresshttps://practicaldermatology.com/news/kenvue-present-new-data-sets-eadv-congress/2468301/Kenvue announced the presentation of seven new data sets at the 2024 European Academy of Dermatology and Venereology (EADV) Congress this week in Amsterdam, Netherlands. The studies will feature Kenvue’s Aveeno and Neutrogena brands, “demonstrating the key to improved skin and hair outcome
- New Photoprotection Data at EADV Congresshttps://practicaldermatology.com/news/new-photoprotection-data-eadv-congress/2468300/Kenvue announced the presentation of two new data sets relating to photoprotection at the 2024 European Academy of Dermatology and Venereology (EADV) Congress this week in Amsterdam, Netherlands. The studies will demonstrate "the key to improved skin and hair outcomes through proactive use
- LEO Pharma Set for Five Late-Breaking Presentations at EADVhttps://practicaldermatology.com/news/leo-pharma-set-five-late-breaking-presentations-eadv/2468299/LEO Pharma A/S will present new clinical and real-world data from across its portfolio of products at the 33rd European Academy of Dermatology and Venereology (EADV) Congress from September 25-28 in Amsterdam, Netherlands, the company announced. Five coveted late-breaking presentations wi
- Lebrikizumab Shows Sustained AD Control Up to 3 Years in More 80%https://practicaldermatology.com/news/lebrikizumab-shows-sustained-ad-control-3-years-more-80/2468297/More than 80% of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to 3 years experienced sustained skin clearance with monthly maintenance dosing, Almirall
- Frontier Acquires Mohs Specialist Doherty Dermatologyhttps://practicaldermatology.com/news/frontier-acquires-mohs-specialist-doherty-dermatology/2468264/Frontier Dermatology announced the acquisition of Doherty Dermatology, a clinic in Bellingham, Washington, that specializes in Mohs micrographic surgery. Doherty Dermatology will be rebranded as Frontier Dermatology (Bellingham South) starting October 1, joining the company's 35 other physician o